Stock Track | Bionano Genomics Plunges 6.44% Pre-market Following CMS Preliminary Payment Determination

Stock Track

Sep 15

Shares of Bionano Genomics (BNGO) tumbled 6.44% in pre-market trading on Monday, following an announcement regarding a preliminary payment determination from the Centers for Medicare & Medicaid Services (CMS) for Optical Genome Mapping (OGM).

Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, revealed that CMS has posted the preliminary payment determination for OGM. While the specifics of the determination were not provided in the initial announcement, the sharp decline in stock price suggests that investors perceive this development as potentially unfavorable for the company.

The market's reaction highlights the significance of CMS reimbursement decisions for healthcare technology companies like Bionano Genomics. Optical Genome Mapping is likely a key offering for the company, and the preliminary payment determination could have substantial implications for its future revenue and adoption of the technology. Investors will be closely watching for more details about the CMS decision and its potential impact on Bionano Genomics' business prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1135407070"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1135407070\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1135407070?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-15 20:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135407070","market":"us","top_or_hot":-1,"title":"Stock Track | Bionano Genomics Plunges 6.44% Pre-market Following CMS Preliminary Payment Determination","media":"Stock Track","content":"<p>Shares of Bionano Genomics (BNGO) tumbled 6.44% in pre-market trading on Monday, following an announcement regarding a preliminary payment determination from the Centers for Medicare &amp; Medicaid Services (CMS) for Optical Genome Mapping (OGM).</p>\n\n<p>Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, revealed that CMS has posted the preliminary payment determination for OGM. While the specifics of the determination were not provided in the initial announcement, the sharp decline in stock price suggests that investors perceive this development as potentially unfavorable for the company.</p>\n\n<p>The market's reaction highlights the significance of CMS reimbursement decisions for healthcare technology companies like Bionano Genomics. Optical Genome Mapping is likely a key offering for the company, and the preliminary payment determination could have substantial implications for its future revenue and adoption of the technology. Investors will be closely watching for more details about the CMS decision and its potential impact on Bionano Genomics' business prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Bionano Genomics Plunges 6.44% Pre-market Following CMS Preliminary Payment Determination</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Bionano Genomics Plunges 6.44% Pre-market Following CMS Preliminary Payment Determination\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-09-15 20:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Bionano Genomics (BNGO) tumbled 6.44% in pre-market trading on Monday, following an announcement regarding a preliminary payment determination from the Centers for Medicare &amp; Medicaid Services (CMS) for Optical Genome Mapping (OGM).</p>\n\n<p>Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, revealed that CMS has posted the preliminary payment determination for OGM. While the specifics of the determination were not provided in the initial announcement, the sharp decline in stock price suggests that investors perceive this development as potentially unfavorable for the company.</p>\n\n<p>The market's reaction highlights the significance of CMS reimbursement decisions for healthcare technology companies like Bionano Genomics. Optical Genome Mapping is likely a key offering for the company, and the preliminary payment determination could have substantial implications for its future revenue and adoption of the technology. Investors will be closely watching for more details about the CMS decision and its potential impact on Bionano Genomics' business prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNGO","symbol_name":"Bionano Genomics","start_time":0,"source_url":"","article_id":"1135407070","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135407070","pubTimestamp":1757939056,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Bionano Genomics (BNGO) tumbled 6.44% in pre-market trading on Monday, following an announcement regarding a preliminary payment determination from the Centers for Medicare & Medicaid...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNGO":"Bionano Genomics"},"translate_title":"个股追踪|Bionano Genomics盘前暴跌6.44%CMS初步付款确定","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNGO":1},"content_text":"Shares of Bionano Genomics (BNGO) tumbled 6.44% in pre-market trading on Monday, following an announcement regarding a preliminary payment determination from the Centers for Medicare & Medicaid Services (CMS) for Optical Genome Mapping (OGM).\nBionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, revealed that CMS has posted the preliminary payment determination for OGM. While the specifics of the determination were not provided in the initial announcement, the sharp decline in stock price suggests that investors perceive this development as potentially unfavorable for the company.\nThe market's reaction highlights the significance of CMS reimbursement decisions for healthcare technology companies like Bionano Genomics. Optical Genome Mapping is likely a key offering for the company, and the preliminary payment determination could have substantial implications for its future revenue and adoption of the technology. Investors will be closely watching for more details about the CMS decision and its potential impact on Bionano Genomics' business prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}